-
Multiple Shots On Goal: Can-Fite's Late-Stage Clinical Pipeline Hits Positive Results
Tuesday, December 13, 2022 - 8:51am | 1047Read More...Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer. These countries, including Romania and Israel, seem to have acknowledged Namodenoson’s high efficacy and...
-
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
Thursday, October 27, 2022 - 8:49am | 858Read More...The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up. Psoriasis is a chronic inflammatory skin disease caused by genetic disposition or environmental factors and is a burgeoning $16 billion global...
-
Attacking Diseases On Multiple Fronts — Pharmaceutical Development Combined With Cannabis?
Tuesday, April 12, 2022 - 9:11am | 626Read More...Picture credit: Esteban Lopez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. While it is developing its own drugs to treat diseases and conditions such as liver cancer and psoriasis, one...
-
This Biotech Company Looks To Be Targeting A New Drug To Treat NASH, The Leading Cause of Liver Transplants
Thursday, March 24, 2022 - 9:11am | 515Read More...This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Israeli biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) recently enrolled the first patient in a study aimed at finding a treatment for non-...
-
Psoriasis Drug Providers Looking Over Shoulders At Upcoming Competitor?
Thursday, February 3, 2022 - 9:33am | 692Read More...Photo by Diana Polekhina on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Pharmaceutical companies involved in psoriasis drug treatment will likely be casting an eye on the outcome of clinical...
-
A New Oral Therapy for Psoriasis Could Be Coming Soon
Monday, January 24, 2022 - 9:34am | 652Read More...Photo by Towfiqu barbhuiya on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The $23 billion psoriasis drug market has a number of well-known pharmaceutical companies vying to get patients to use...
-
PRIOR TO PHASE III PSORIASIS DATA RELEASE CAN FITE REPORTS THAT PICLIDENOSON DESTROYS PATHOLOGICAL SKIN CELLS IN VITRO
Thursday, January 13, 2022 - 8:42am | 1219Read More...Piclidenoson has been out-licensed for the indication of psoriasis in certain major markets PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address...
-
Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference
Monday, January 10, 2022 - 8:39am | 1339Read More...PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, announced today that it will hold one-on-one virtual investor meetings during...
-
Dawson James - Can-Fite (CANF) Buy Rated - Expected Milestones
Wednesday, January 5, 2022 - 12:58pm | 623Read More...Can-Fite in a letter to shareholders outlined the milestones ahead for the year. Click here for the full report COMFORT-Plaque Psoriasis: Topline Phase 3 Psoriasis Data Expected Q122 Comfort Phase 3 study of Piclidenoson enrolled and treated approximately 400 patients with moderate to...
-
CAN-FITE ISSUES LETTER TO SHAREHOLDERS
Wednesday, January 5, 2022 - 8:41am | 1778Read More...Q1 2022: Psoriasis Phase III Data & Commencement of Enrollment in Phase IIb NASH H1 2022: Commencement of Enrollment in Phase III Liver Cancer PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company...
-
FOLLOWING COMPLETE CLEARANCE OF CANCER LESIONS IN ADVANCED LIVER CANCER PATIENT, CAN-FITE IS FILING PATENT APPLICATIONS FOR THE TREATMENT OF VARIOUS ADVANCED SOLID TUMORS
Monday, January 3, 2022 - 11:24am | 1372Read More...Namodenoson Headed into Pivotal Phase III Liver Cancer Study PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases...
-
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
Thursday, October 21, 2021 - 9:25am | 1339Read More...The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing...
-
Piclidenoson From Can-Fite Biopharma Shows New, Promising Developments For Psoriasis Treatment
Tuesday, January 19, 2021 - 2:26pm | 1115Read More...The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. In the era of constant development and innovation, there is still a lot to learn about the human body and how certain diseases...
-
Earnings Roundup: iAnthus, Can-Fite, Organigram, Bluma Wellness, Auxly
Monday, November 30, 2020 - 1:39pm | 1022Read More...iAnthus Touts 82% YoY Revenue Growth, Names Interim COO New York-based iAnthus Capital Holdings Inc. (CSE: IAN) (PINK: ITHUF) generated around $40.6 million in revenue during the third quarter of fiscal 2020. That's up by 17% sequentially and roughly 82% year-over-year. The...
